Prostate CANCT06612034
Prostate Cancer Care Disparity Analysis Project (ProGAP)
An observational study of Prostate CA, run by Ankara University at 1 site in Turkey (Türkiye).
Trial summary
This international cross-sectional study seeks to evaluate global disparities in prostate cancer management by conducting a thorough comparison of key elements across countries categorized as low-income, lower-middle-income, upper-middle-income, and high-income. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Prostate CA
- How many people
- 400 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 10 Mar 2025to 30 Oct 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Healthcare professionals actively treating prostate cancer patients-such as urologists, uro-oncologists, medical oncologists, and radiation oncologists-who specialize in the diagnosis and treatment of prostate cancer, representing a diverse range of countries categorized as low-income, lower-middle-income, upper-middle-income, and high-income
Who may be able to join
- Urologists, Uro-oncologists, Medical oncologists, Radiation oncologists
Who cannot join
- Non-clinical healthcare professionals Healthcare professionals not directly involved in the care of prostate cancer patients, Healthcare professionals with missing or incorrect email addresses
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Ankara University Faculty of Medicine
Ankara, Ankara, 06590
Yüksel Ürün, M.D., +905304517798, yukselurun@gmail.com
Satı Coşkun Yazgan, M.D., +903125883061, coskunyazgann491@gmail.com
About this study
Official title: Evaluating the Worldwide Landscape of Prostate Cancer Management
This international cross-sectional study seeks to evaluate global disparities in prostate cancer management by conducting a thorough comparison of key elements across countries categorized as low-income, lower-middle-income, upper-middle-income, and high-income.
The primary question it addresses is: Are the standards of care for prostate cancer uniformly applied across different geographic regions worldwide? To achieve this, we will recruit physicians specializing in the diagnosis and treatment of prostate cancer from a diverse array of countries within these income classifications. Participants will complete a 17-question online survey.
Read the detailed description
Prostate cancer stands as one of the most common cancers among men worldwide, with outcomes and care quality significantly varying due to a multitude of factors including geographic location, healthcare infrastructure, socioeconomic status, and clinical practices. The ProGAP project is conceived to delve into these variations, providing a detailed examination of the global landscape of prostate cancer care.
Objectives:
- To systematically gather and analyze data on current diagnostic methods, treatment modalities, and management practices for prostate cancer from a wide range of countries and healthcare settings.
- To identify and quantify disparities in access to and availability of standard care, novel treatments, and supportive services for patients with prostate cancer.
- To evaluate the adherence levels to both international and national guidelines in prostate cancer treatment across diverse healthcare systems.
Methods:
The ProGAP survey will be distributed internationally to healthcare professionals, including urologists, uro-oncologists, medical oncologists, and radiation oncologists, who are actively involved in prostate cancer care. The survey will comprehensively cover demographic details, clinical practice environment, patient demographics and stages managed, guideline adherence, availability and use of diagnostic and treatment options, and multidisciplinary care approaches. A survey and a consent form will be sent to study participants in addition to written information about the study. Completing surveys will take 10-12 minutes. Participants will complete a 17-question online survey. The first part of the form includes questions about demographics and hospital characteristics. The second part contains questions about prostate cancer diagnosis, treatment, and management practices. Participation in this study is entirely voluntary and anonymous. Neither sensitive personal data nor contact information will be collected during the research. This research does not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors, and the investigators declare that they do not have any conflict of interest with the work.
Data Analysis Plan:
Statistical analyses will employ both descriptive and inferential statistics to interpret the survey data. Comparative analyses will be conducted to uncover disparities across different regions and healthcare settings. Advanced statistical methods, such as regression analysis, may be utilized to explore factors associated with variations in care practices and outcomes.
Expected Impact:
By elucidating the disparities in prostate cancer care worldwide, ProGAP aims to stimulate policy changes, guide improvements in clinical practice, and foster international collaborations to enhance the quality of care and outcomes for patients with prostate cancer globally. Insights gained from this project are anticipated to inform stakeholders, including healthcare providers, policymakers, and patient advocacy groups, about critical areas for intervention and improvement.
- Conditions
- Prostate CA
- Being tested
- No Intervention: Observational Cohort
- Keywords
- prostate cancer, Human Development Index, survey, access to medicine, multidisciplinary care
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortOther
No Intervention: Observational Cohort
| Study group | Role | What they receive |
|---|---|---|
| Healthcare professionals for prostate cancer | Healthcare professionals actively engaged in prostate cancer treatment, including urologists, uro-oncologists, medical oncologists, and radiation oncologists Receives: Other: No Intervention: Observational Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
Characterization of global disparities in prostate cancer diagnosis, treatment, and management practices
Comparative analyses will be conducted using survey data to reveal disparities between different regions and healthcare settings. The findings will be presented as percentages of respondents, with territorial and institutional differences thoroughly evaluated. Participants will be categorized into three groups based on the World Bank\'s income classification: low and lower-middle, upper-middle, and high-income countries. Descriptive statistics will be employed to compare demographic characteristics and clinical practices. For categorical data analysis, the Pearson Chi-Square or Fisher\'s Exact test will be utilized, while ANOVA tests will be applied to independent variables. A p-value of less than 0.05 will be considered statistically significant.
Measured: One month
Secondary outcomes (1)
Assessment of access to care, encompassing advanced diagnostic tools, treatment modalities, and patient support services; analysis of adherence to guidelines and its effect on treatment outcomes
Identifying the percentage of healthcare professionals across various geographic regions who have access to diagnostic and treatment methods that align with established guidelines, and evaluating the impact of these methods on treatment outcomes. The findings will be presented as percentages of respondents, with territorial and institutional differences thoroughly examined.
Measured: One month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2024
- Study start10 Mar 2025
- Primary completion30 Oct 2025 (estimated)
- Study completion30 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CAStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 400 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Ankara University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yüksel Ürün, Ankara University
- Investigators
- Yüksel Ürün, Study director, Ankara UniversityDeborah Mukherji, Study director, Clemenceau Medical Center Hospital DubaiMohammed Shahait, Study director, Al Zahra Hospital DubaiLuis Castelo Branco, Study director, IOSI Oncologist Institute of Southern Switzerland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06612034
- Sponsor's protocol ID
- ANKARA-UNIVERSITY-YURUN-01
- Status last verified
- Sep 2024
- First submitted
- 21 Sep 2024
- Last updated
- 24 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data that support the findings of this study are available from the study director upon reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Worldwide Landscape of Prostate Cancer Management
- ClinicalTrials.gov ID
- NCT06612034
- Acronym / sponsor ID
- ANKARA-UNIVERSITY-YURUN-01
- Conditions
- Prostate CA
- Keywords
- prostate cancer, Human Development Index, survey, access to medicine, multidisciplinary care
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Ankara UniversityUniversity, hospital or other
- Study start
- 10 Mar 2025 (actual)
- Primary completion
- 30 Oct 2025 (estimated)
- Study completion
- 30 Oct 2025 (estimated)
- First posted
- 25 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This international cross-sectional study seeks to evaluate global disparities in prostate cancer management by conducting a thorough comparison of key elements across countries categorized as low-income, lower-middle-income, upper-middle-income, and high-income.
The primary question it addresses is: Are the standards of care for prostate cancer uniformly applied across different geographic regions worldwide? To achieve this, we will recruit physicians specializing in the diagnosis and treatment of prostate cancer from a diverse array of countries within these income classifications. Participants will complete a 17-question online survey.
Detailed description
Prostate cancer stands as one of the most common cancers among men worldwide, with outcomes and care quality significantly varying due to a multitude of factors including geographic location, healthcare infrastructure, socioeconomic status, and clinical practices. The ProGAP project is conceived to delve into these variations, providing a detailed examination of the global landscape of prostate cancer care.
Objectives:
- To systematically gather and analyze data on current diagnostic methods, treatment modalities, and management practices for prostate cancer from a wide range of countries and healthcare settings.
- To identify and quantify disparities in access to and availability of standard care, novel treatments, and supportive services for patients with prostate cancer.
- To evaluate the adherence levels to both international and national guidelines in prostate cancer treatment across diverse healthcare systems.
Methods:
The ProGAP survey will be distributed internationally to healthcare professionals, including urologists, uro-oncologists, medical oncologists, and radiation oncologists, who are actively involved in prostate cancer care. The survey will comprehensively cover demographic details, clinical practice environment, patient demographics and stages managed, guideline adherence, availability and use of diagnostic and treatment options, and multidisciplinary care approaches. A survey and a consent form will be sent to study participants in addition to written information about the study. Completing surveys will take 10-12 minutes. Participants will complete a 17-question online survey. The first part of the form includes questions about demographics and hospital characteristics. The second part contains questions about prostate cancer diagnosis, treatment, and management practices. Participation in this study is entirely voluntary and anonymous. Neither sensitive personal data nor contact information will be collected during the research. This research does not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors, and the investigators declare that they do not have any conflict of interest with the work.
Data Analysis Plan:
Statistical analyses will employ both descriptive and inferential statistics to interpret the survey data. Comparative analyses will be conducted to uncover disparities across different regions and healthcare settings. Advanced statistical methods, such as regression analysis, may be utilized to explore factors associated with variations in care practices and outcomes.
Expected Impact:
By elucidating the disparities in prostate cancer care worldwide, ProGAP aims to stimulate policy changes, guide improvements in clinical practice, and foster international collaborations to enhance the quality of care and outcomes for patients with prostate cancer globally. Insights gained from this project are anticipated to inform stakeholders, including healthcare providers, policymakers, and patient advocacy groups, about critical areas for intervention and improvement.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Healthcare professionals for prostate cancer | – | Other: No Intervention: Observational CohortHealthcare professionals actively engaged in prostate cancer treatment, including urologists, uro-oncologists, medical oncologists, and radiation oncologists |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Healthcare professionals actively treating prostate cancer patients-such as urologists, uro-oncologists, medical oncologists, and radiation oncologists-who specialize in the diagnosis and treatment of prostate cancer, representing a diverse range of countries categorized as low-income, lower-middle-income, upper-middle-income, and high-income
Key inclusion criteria (1 listed)
- Urologists, Uro-oncologists, Medical oncologists, Radiation oncologists
Key exclusion criteria (1 listed)
- Non-clinical healthcare professionals Healthcare professionals not directly involved in the care of prostate cancer patients, Healthcare professionals with missing or incorrect email addresses
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational CohortNo Intervention: Observational Cohort | Other | Healthcare professionals for prostate cancer |
Primary outcome
Characterization of global disparities in prostate cancer diagnosis, treatment, and management practices
Time frame: One month
Comparative analyses will be conducted using survey data to reveal disparities between different regions and healthcare settings. The findings will be presented as percentages of respondents, with territorial and institutional differences thoroughly evaluated. Participants will be categorized into three groups based on the World Bank\'s income classification: low and lower-middle, upper-middle, and high-income countries. Descriptive statistics will be employed to compare demographic characteristics and clinical practices. For categorical data analysis, the Pearson Chi-Square or Fisher\'s Exact test will be utilized, while ANOVA tests will be applied to independent variables. A p-value of less than 0.05 will be considered statistically significant.
1 secondary outcome
Assessment of access to care, encompassing advanced diagnostic tools, treatment modalities, and patient support services; analysis of adherence to guidelines and its effect on treatment outcomes
Time frame: One month
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2025.
- Individual participant dataSharing planned: No. The data that support the findings of this study are available from the study director upon reasonable request.
Related trials for Prostate CA
Enrolling by invitationObservational study
Patient Empowerment Via Mobile Health Applications (MHAs)
Empowerment, Patient, Mobile Application
Not yet recruiting
Prostate MRI Analysis by Radiologists and Artificial Intelligence - Disease Identification and Guided Management
Prostate CA
RecruitingPhase 2
Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer
Prostate CA
RecruitingObservational study
Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study
Prostate CA
RecruitingPhase 1
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
Prostate CA, Prostate Cancer (Adenocarcinoma)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yüksel Ürün study director
Ankara University
Deborah Mukherji study director
Clemenceau Medical Center Hospital Dubai
Mohammed Shahait study director
Al Zahra Hospital Dubai
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prostate CA, run by Ankara University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yüksel Ürün (800-555-5555, yukselurun@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Characterization of global disparities in prostate cancer diagnosis, treatment, and management practices (time frame: One month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2025.